Our goal was to identify novel peptide scaffolds that are able to antagonize the PD1 receptor to interrogate the utility of the checkpoint receptor inhibitors as a T-cell adjuvant that can enhance the immunogenicity and protective efficacy of certain infectious disease vaccines by expanding vaccine-induced CD8+ T-cell responses. This evidence concerns the gene CD8A and infectious disease.